Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Beta-lactam allergy is the most prevalent drug allergy. Drug eruption is the most common
symptom whereas life-threatening anaphylaxis is rather rare. A recently published study
(Journal of Allergy and Clinical Immunology, January 2011, Vol. 127, p. 218-222) described
the safety of a 2-day oral beta-lactam challenge in penicillin-allergic patients,
disregarding their penicillin skin test results. In the proposed study the investigators will
similarly challenge beta-lactam allergic patients, both children and adults for an extended
(5 days) period of time. The study will include patients with a history of a skin rash
following beta-lactam administration as well as patients who cannot provide any data on their
presumed allergic reaction, disregarding their penicillin skin test results.